The Clinicopathological Characteristics of Palpable and Non-palpable Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Palpability is known to be a poor prognostic factor for breast cancer. The present study analyzed the clinicopathological characteristics and outcomes of palpable and nonpalpable breast cancers using big data. Methods: Between January 2005 and May 2019, a total of 15,141 patients were enrolled. All patients were diagnosed with invasive ductal carcinomas. Patients with unclear medical records, multiple tumors, bilateral breast cancers, inflammatory breast cancers, inoperable breast cancers and distant metastasis were excluded. Patients were divided into the palpable and nonpalpable breast cancer groups based on physicians’ clinical examinations. The clinicopathological characteristics and disease-specific survivals (DSS) were analyzed. Results: Patients with palpable breast cancers were younger, had larger tumors, and higher tumor-node-metastasis stage (p<0.001) than patients with nonpalpable breast cancers. Palpable breast cancer cases had higher rates of lympho-vascular invasion, higher histologic and nuclear grades than nonpalpable breast cancer cases (p<0.001). The positive proportion of hormone receptor was higher in the nonpalpable breast cancer group than in the palpable breast cancer group, but that of human epidermal growth factor receptor 2 was higher in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). The Ki-67 index was higher in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). Total mastectomy and axillary dissection were performed more frequently in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). Adjuvant chemotherapy was administered more frequently in the palpable breast cancer group than in the nonpalpable breast cancer group. However, radiotherapy and hormonal therapy were performed more frequently in nonpalpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). According to a multivariate analysis, younger age, lower body mass index, larger tumor size, tumor location, higher stage, higher histologic grade and higher Ki-67 index were associated with palpability (p<0.001). DSS was significantly lower in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). Conclusion: Palpable breast cancers tend to be triple negative breast cancers and have higher histologic grade and, Ki-67 index and worse prognosis than nonpalpable breast cancers. Therefore, based on the results of the present study, treating palpable breast cancers requires careful attention.
Abstract
Purpose: Palpability is known to be a poor prognostic factor for breast cancer. The present study analyzed the clinicopathological characteristics and outcomes of palpable and nonpalpable breast cancers using big data. Methods: Between January 2005 and May 2019, a total of 15,141 patients were enrolled. All patients were diagnosed with invasive ductal carcinomas. Patients with unclear medical records, multiple tumors, bilateral breast cancers, inflammatory breast cancers, inoperable breast cancers and distant metastasis were excluded. Patients were divided into the palpable and nonpalpable breast cancer groups based on physicians’ clinical examinations. The clinicopathological characteristics and disease-specific survivals (DSS) were analyzed. Results: Patients with palpable breast cancers were younger, had larger tumors, and higher tumor-node-metastasis stage (p<0.001) than patients with nonpalpable breast cancers. Palpable breast cancer cases had higher rates of lympho-vascular invasion, higher histologic and nuclear grades than nonpalpable breast cancer cases (p<0.001). The positive proportion of hormone receptor was higher in the nonpalpable breast cancer group than in the palpable breast cancer group, but that of human epidermal growth factor receptor 2 was higher in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). The Ki-67 index was higher in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). Total mastectomy and axillary dissection were performed more frequently in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). Adjuvant chemotherapy was administered more frequently in the palpable breast cancer group than in the nonpalpable breast cancer group. However, radiotherapy and hormonal therapy were performed more frequently in nonpalpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). According to a multivariate analysis, younger age, lower body mass index, larger tumor size, tumor location, higher stage, higher histologic grade and higher Ki-67 index were associated with palpability (p<0.001). DSS was significantly lower in the palpable breast cancer group than in the nonpalpable breast cancer group (p<0.001). Conclusion: Palpable breast cancers tend to be triple negative breast cancers and have higher histologic grade and, Ki-67 index and worse prognosis than nonpalpable breast cancers. Therefore, based on the results of the present study, treating palpable breast cancers requires careful attention.
참고문헌 (18)
- Independent UK panel on breast cancer screening, "The benefits and harms of breast cancer screening: an independent review", Lancet, 380, pp.1778~1786 (2012)
- Myers ER, "Benefits and harms of breast cancer screening : a systematic review", JAMA, 314, pp.1615~1634 (2015)
- Jorgensen KJ, "Overdiagnosis in publicly organised mammography screening programmes : systematic review of incidence trends", BMJ, 339, pp.b2587~ (2009)
- Kalager M, "Overdiagnosis of invasive breast cancer due to mammography screening : results from the Norwegian screening program", Ann Intern Med, 156, pp.491~499 (2012)
- Bjurstam N, "The Gothenburg breast screening trial", Cancer, 97, pp.2387~2396 (2003)
- Moss SM, "Effect of mammographic screening from age 40 years on breast cancer mortality in the UK age trial at 17 years’ follow-up : a randomised controlled trial", Lancet Oncol, 16, pp.1123~1132 (2015)
- 김이삭, "미세 석회화를 동반한 비촉지성 유방병소에서 나타나는 악성군의 특징", Journal of Breast Disease, 2(1), pp.16~21 (2014), 한국유방암학회[DOI]
- 민선영, "The Basic Facts of Korean Breast Cancer in 2013: Results of a Nationwide Survey and Breast Cancer Registry Database", Journal of Breast Cancer, 19(1), pp.1~7 (2016), 한국유방암학회
- 박은화, "Basic Facts of Breast Cancer in Korea in 2014: The 10-Year Overall Survival Progress", Journal of Breast Cancer, 20(1), pp.1~11 (2017), 한국유방암학회[DOI]
- Skinner KA, "Palpable breast cancers are inherently different from nonpalpable breast cancers", Ann Surg Oncol, 8, pp.705~710 (2001)
- Warren SL, "Differences between palpable and nonpalpable tumors in early-stage, hormone receptor-positive breast cancer", Am J Surg, 216, pp.326~330 (2018)
- Kwan ML, "Pre-diagnosis body mass index and survival after breast cancer in the after breast cancer pooling project", Breast Cancer Res Treat, 132, pp.729~739 (2012)
- Niraula S, "Body size and breast cancer prognosis in relation to hormone receptor and menopausal status : a meta-analysis", Breast Cancer Res Treat, 134, pp.769~781 (2012)
- Silverstein MJ, "Predicting axillary nodal positivity in 2282 patients with breast carcinoma", World J Surg, 25, pp.767~772 (2001)
- Chao C, "Palpable breast carcinomas : a hypothesis for clinically relevant lymphatic drainage in sentinel lymph node biopsy", Breast J, 9, pp.26~32 (2003)
- Olivotto IA, "Prediction of axillary lymph node involvement of women with invasive breast carcinoma : a multivariate analysis", Cancer, 83, pp.948~955 (1998)
- Li Z, "Clinical characteristics and outcomes of single versus double hormone receptor-positive breast cancer in 2 large databases", Clin Breast Cancer, 20, pp.e151~63 (2020)
- Rossi L, "Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy", Cancer Chemother Pharmacol, 85, pp.105~111 (2020)